Changing Treatment Trends for Advanced Breast Cancer Patients

In recent years, doctors have been exploring the use of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for a specific group of breast cancer patients. These patients, known as cN3b, have cancer that has spread to both their armpit and the lymph nodes near their breastbone. The study looked into how often SLNB was used for these patients and whether it affected their survival rates, especially for those who had a complete response to treatment.

The researchers found that more doctors are now using SLNB for cN3b patients after they finish NAC. This procedure is less invasive than a full lymph node dissection. However, the study also showed that the survival rates for patients who had a complete nodal pathologic response (nPCR) were similar, regardless of whether they had SLNB or the more extensive lymph node surgery. This information is crucial for both patients and doctors. It suggests that for some cN3b patients, the less invasive SLNB might be just as effective in managing their cancer. But it's important to note that more research is needed to confirm these findings and to understand which patients might benefit the most from this approach.

Actions